TRANSFER OF HIV-1-SPECIFIC CYTOTOXIC T-LYMPHOCYTES TO AN AIDS PATIENT LEADS TO SELECTION FOR MUTANT HIV VARIANTS AND SUBSEQUENT DISEASE PROGRESSION

被引:320
作者
KOENIG, S
CONLEY, AJ
BREWAH, YA
JONES, GM
LEATH, S
BOOTS, LJ
DAVEY, V
PANTALEO, G
DEMAREST, JF
CARTER, C
WANNEBO, C
YANNELLI, JR
ROSENBERG, SA
LANE, HC
机构
[1] MERCK RES LABS, West Point, PA 19486 USA
[2] NIAID, IMMUNOREGULAT LAB, BETHESDA, MD 20892 USA
[3] NCI, CTR CLIN, TRANSFUS MED BRANCH, BETHESDA, MD 20892 USA
[4] NCI, SURG BRANCH, BETHESDA, MD 20892 USA
关键词
D O I
10.1038/nm0495-330
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
An HIV-1-seropositive volunteer was infused with an expanded autologous cytotoxic T lymphocyte (CTL) clone directed against the HIV-1 nef protein. This clone was adoptively transferred to determine whether supplementing CTL activity could reduce viral load or improve clinical course. Unexpectedly, infusion was followed by a decline in circulating CD4(-) T cells and a rise in viral load. Some of the HIV isolates obtained from the plasma or CD4(-) cells of the patient were lacking the nef epitope. These results suggest that active CTL selection of viral variants could contribute to the pathogenesis of AIDS and that clinical progression can occur despite high levels of circulating HIV-1-specific CTLs.
引用
收藏
页码:330 / 336
页数:7
相关论文
共 40 条
  • [1] BINDER D, 1991, J IMMUNOL, V146, P4301
  • [2] QUANTITATIVE-ANALYSIS OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1)-SPECIFIC CYTOTOXIC LYMPHOCYTE-T (CTL) RESPONSE AT DIFFERENT STAGES OF HIV-1 INFECTION - DIFFERENTIAL CTL RESPONSES TO HIV-1 AND EPSTEIN-BARR-VIRUS IN LATE DISEASE
    CARMICHAEL, A
    JIN, X
    SISSONS, P
    BORYSIEWICZ, L
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 177 (02) : 249 - 256
  • [3] CHEN ZW, 1993, J IMMUNOL, V151, P2177
  • [4] IMPAIRED CYTOTOXIC T-LYMPHOCYTE RECOGNITION DUE TO GENETIC VARIATIONS IN THE MAIN IMMUNOGENIC REGION OF THE HUMAN-IMMUNODEFICIENCY-VIRUS-1 NEF PROTEIN
    COUILLIN, I
    CULMANNPENCIOLELLI, B
    GOMARD, E
    CHOPPIN, J
    LEVY, JP
    GUILLET, JG
    SARAGOSTI, S
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 180 (03) : 1129 - 1134
  • [5] CULMANN B, 1991, J IMMUNOL, V146, P1560
  • [6] DAI L C, 1992, Journal of Virology, V66, P3151
  • [7] PROTECTIVE EFFECTS OF A LIVE ATTENUATED SIV VACCINE WITH A DELETION IN THE NEF GENE
    DANIEL, MD
    KIRCHHOFF, F
    CZAJAK, SC
    SEHGAL, PK
    DESROSIERS, RC
    [J]. SCIENCE, 1992, 258 (5090) : 1938 - 1941
  • [8] PROTECTION AGAINST LETHAL CYTOMEGALOVIRUS-INFECTION BY A RECOMBINANT VACCINE CONTAINING A SINGLE NONAMERIC T-CELL EPITOPE
    DELVAL, M
    SCHLICHT, HJ
    VOLKMER, H
    MESSERLE, M
    REDDEHASE, MJ
    KOSZINOWSKI, UH
    [J]. JOURNAL OF VIROLOGY, 1991, 65 (07) : 3641 - 3646
  • [9] INDUCTION OF PROTECTIVE CLASS-I MHC-RESTRICTED CTL IN MICE BY A RECOMBINANT INFLUENZA VACCINE IN ALUMINUM HYDROXIDE ADJUVANT
    DILLON, SB
    DEMUTH, SG
    SCHNEIDER, MA
    WESTON, CB
    JONES, CS
    YOUNG, JF
    SCOTT, M
    BHATNAGHAR, PK
    LOCASTRO, S
    HANNA, N
    [J]. VACCINE, 1992, 10 (05) : 309 - 318
  • [10] BIOLOGICAL AND BIOCHEMICAL-CHARACTERIZATION OF A CLONED LEU-3- CELL SURVIVING INFECTION WITH THE ACQUIRED-IMMUNE-DEFICIENCY-SYNDROME RETROVIRUS
    FOLKS, TM
    POWELL, D
    LIGHTFOOTE, M
    KOENIG, S
    FAUCI, AS
    BENN, S
    RABSON, A
    DAUGHERTY, D
    GENDELMAN, HE
    HOGGAN, MD
    VENKATESAN, S
    MARTIN, MA
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1986, 164 (01) : 280 - 290